Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
|Articles|November 20, 2012
Mini-Quiz: Atypical Depression
It was not until the introduction of this MAOI that the term “atypical depression” began to emerge to describe a particular variant of nonendogenous depression.
Advertisement
It was not until the introduction of the first monoamine oxidase inhibitor (MAOI) that the term “atypical depression” began to emerge to describe a particular variant of nonendogenous depression. What was the name of that MAOI?
For the answer,
Answer: e, iproniazid
It was not until the introduction of the first MAOI-iproniazid-that the term “atypical depression” began to emerge to describe a particular variant of nonendogenous depression. For more on this topic, see "
Advertisement
Related to this article
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Ketamine or esketamine during C-section anesthesia lowers early postpartum depression symptom scores in trials, hinting at a new prevention approach under study.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
2
Improving but Not Feeling It: Anticipatory Anhedonia and Cognition
3
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
4
Positive Topline Results From Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
5